Halozyme Therapeutics, an oncology biotech company headquartered in San Diego, has announced its chief financial officer David Ramsay will retire this summer, and named biotech veteran Laurie Stelzer as his successor. Stelzer will assume chief financial officer  duties on June 15 and will work with Ramsay through a transition period.

"Since last year, David and I have been working closely to plan for his eventual retirement," said Dr. Helen Torley, president and CEO. "David helped guide Halozyme for more than a decade as the company built a significant partner model with our Enhanze platform and more recently as we laid the foundation for the development of our oncology programs.”

Torley said, "As we prepare for the regulatory submissions and commercialization upon approval of our investigational new drug PEGH20 in the U.S. and Europe, Stelzer brings unique experience gained by supporting similar commercial plans at Amgen and Shire." 

At Shire, Stelzer served as senior vice president of finance for R&D, technical operations and business development, and previously was division chief financial officer for regenerative medicine. She also spent 15 years at Amgen, in senior leadership roles in finance and business development with responsibilities including the U.S., Canada and International Markets, ultimately serving as the company's acting treasurer.